Digital Therapeutics

Supporting Clinical Research in Digital Therapeutics

Digital Therapeutics (DTx) is a cutting-edge field that uses software, either alone or in combination with drugs or devices, to deliver evidence-based treatments to patients. These innovative therapies represent unique challenges when it comes to the design and execution of clinical trials that can support regulatory approvals. At VeraSci, our team has direct experience working with Digital Therapeutics, including working with sponsors to select and develop appropriate assessments and endpoints, address the particular challenges of digital placebos (sham treatments), and manage data collection challenges (in clinic,  at home, and hybrid visit structures). We can help you design studies and select endpoints that will be accepted by regulators, payers, and patients.

VeraSci Supports Akili’s Study of a Novel Digital Therapeutic in
Pediatric ADHD

The Akili STARS-ADHD Clinical Trial

Richard Keefe, PhD

Co-Founder & CEO

Mark Skeen, MD

Senior Medical Scientist

Luca Pani, MD

VP, Regulatory Strategy and Market Access Innovation

William P. Horan, PhD

VP, Clinical Science

Dependable Solutions for Global Clinical Trials

VeraSci is not just there in the beginning; we take care of your study objectives and data throughout the entire trial. As your partner, we leverage experience gained through hundreds of trials and ensure the highest quality data, all while anticipating any issues that can derail or delay your study before they arise.


We provide expert solutions in: